Ipamorelin: Selective GHS-R1a Agonism and How It Differs from CJC-1295

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) and selective agonist of the ghrelin receptor (GHS-R1a), investigated for its growth hormone-stimulatory profile and notably clean selectivity — it does not significantly stimulate ACTH, cortisol, or prolactin release at research concentrations. This selectivity distinguishes it from earlier growth hormone-releasing peptides (GHRPs) and makes it a useful research tool for isolating GHS-R1a-mediated signalling from broader hypothalamic-pituitary axis effects.

Structure and classification

Ipamorelin belongs to the growth hormone secretagogue (GHS) class — synthetic compounds that stimulate GH release through the ghrelin receptor rather than the GHRH receptor pathway. It is a pentapeptide: five amino acids in sequence, with key structural features that confer both receptor affinity and metabolic stability.

The sequence uses non-natural amino acids: Aib (α-aminoisobutyric acid) at position 1 resists DPP-4 cleavage, D-2-Nal (D-2-naphthylalanine) at position 3 and D-Phe at position 4 are D-amino acid substitutions that improve proteolytic stability and receptor binding geometry. The C-terminal Lys-NH₂ (lysine amide) replaces the free acid found in native peptides, further extending half-life. The combined effect is a half-life of approximately 2 hours — short relative to GHRH analogues but substantially longer than native GHRP-2 or GHRP-6.

Molecular weight is 711.9 Da. At this size it passes the renal filtration threshold, which is why the half-life is measured in hours rather than days.

Receptor mechanism: GHS-R1a

The ghrelin receptor (GHS-R1a) is a class A G-protein coupled receptor expressed primarily on pituitary somatotrophs, hypothalamic neurons, and — at lower levels — cardiac muscle, pancreatic islets, and the gastrointestinal tract. Activation by ipamorelin triggers Gαq-mediated phospholipase C activation, IP3 generation, and intracellular calcium release, which drives GH secretion from somatotroph cells.

This is mechanistically distinct from the GHRH receptor pathway (Gαs/cAMP/PKA) used by CJC-1295 and tesamorelin. The two pathways are synergistic — GHRH receptor activation and GHS-R1a activation together produce more GH release than either alone, which is why ipamorelin and CJC-1295 are commonly studied in combination in the published literature.

Selectivity: what ipamorelin does not stimulate

The defining characteristic of ipamorelin relative to earlier GHRPs is its selectivity profile. Earlier compounds in this class — GHRP-2 and GHRP-6 in particular — stimulate GH release but also significantly elevate ACTH (and therefore cortisol) and prolactin. This limits their utility as research tools for isolating specific GH axis effects.

Ipamorelin does not produce significant ACTH or cortisol elevation at doses that stimulate GH release in published animal studies. Prolactin stimulation is also minimal. This selectivity was demonstrated in the original characterisation by Raun et al. (1998) and has been replicated in subsequent preclinical work. For research protocols requiring clean GH axis stimulation without confounding HPA axis activation, ipamorelin offers a meaningful methodological advantage over earlier GHRPs.

Published preclinical data

GH and IGF-1 stimulation

The primary preclinical literature demonstrates dose-dependent GH release in rat models following ipamorelin administration, with maximal effect at approximately 10-100 µg/kg in published studies. IGF-1 elevation follows the GH pulse with the typical 6-8 hour delay. The pulsatile pattern of GH release is preserved — ipamorelin triggers a pulse rather than producing sustained elevation, consistent with physiological GH secretion dynamics.

Bone density research

A published rat study (Svensson et al., 1998) demonstrated increased cortical bone mass and bone mineral density with ipamorelin treatment compared to vehicle controls, proposed to be secondary to IGF-1-mediated osteoblast activity. This has been a cited rationale for its use as a research tool in bone metabolism models.

Body composition models

Several rodent studies have examined ipamorelin in aged animal models, where endogenous GH secretion is reduced. Results consistently show increased lean mass and reduced fat mass relative to controls, attributed to elevated GH/IGF-1 signalling. These studies are pharmacodynamic rather than mechanistic and are subject to the usual limitations of rodent-to-human translation.

Ipamorelin vs CJC-1295: key distinctions for research design

These two compounds are frequently studied together but act through different receptors and have different profiles:

• Receptor: Ipamorelin targets GHS-R1a (ghrelin receptor); CJC-1295 targets GHRHR (GHRH receptor). Different Gα coupling, different downstream cascades.
• Half-life: Ipamorelin ~2 hours; CJC-1295 without DAC ~30 min; CJC-1295 with DAC several days. For pulsatility studies, ipamorelin is the cleaner tool.
• Selectivity: Ipamorelin does not stimulate ACTH/cortisol; CJC-1295 has a minimal cortisol effect but the comparison matters for protocol design.
• Synergy: The combination of GHS-R1a agonism (ipamorelin) + GHRH receptor agonism (CJC-1295) is additive to synergistic in animal models — useful for maximal GH axis stimulation protocols.
• Clinical evidence: Ipamorelin has published Phase 1 human data (Greenwood et al.) confirming the selectivity profile. CJC-1295 has a smaller human dataset.

For comparative GH secretagogue pharmacology, having both compounds available from the same verified source reduces inter-experiment variability. Ipamorelin is available in our research catalogue. For GHRH axis work, see also CJC-1295 with DAC.

Handling and storage notes

Ipamorelin is a small, stable pentapeptide that reconstitutes readily in sterile water. The non-natural amino acids (Aib, D-2-Nal, D-Phe) make it more resistant to proteolytic degradation than native peptides — reconstituted solutions are relatively stable at 2-8°C for up to 30 days when stored in low-binding tubes. Standard lyophilised storage applies: 2-8°C, protected from moisture and light. See our reconstitution and storage guide for full handling protocol.

Australian regulatory status

Ipamorelin is a Schedule 4 substance under the TGA Poisons Standard. It is not listed on the ARTG and is supplied for in vitro laboratory and educational research only. See our Australian regulatory guide for the full RUO framework.

Key references

• Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.
• Svensson J et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab. 1998;83(2):362-369.
• Greenwood FC et al. Growth hormone secretagogues: clinical prospects. Clin Endocrinol. 1999.

For structural context on how GH secretagogues relate to the broader peptide classes, see our peptide classes overview.